Inhibikase Therapeutics reported a net loss of $19.6 million ($0.11 per share) for the quarter ended June 30, 2026, compared to a $9.9 million loss in the prior year period. Cash and marketable securities totaled $159.0 million as of June 30, with an additional $50 million raised in July through the sale of 25 million shares to RA Capital Management via its at-the-market facility. The company advanced its Phase 3 IMPROVE-PAH study for IKT-001, securing regulatory approvals in 26 countries and initiating 43 clinical sites. Additionally, the FDA granted Orphan Drug Designation for IKT-001. Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing therapeutics to modify cardiopulmonary diseases, specifically Pulmonary Arterial Hypertension.
